Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study.
Daniela PuglieseGiuseppe PriviteraFrancesca RogaiAngela VariolaAnna ViolaLucrezia LaterzaAntonino C PriviteraMariangela AlloccaFabrizio BossaMaria CappelloMarco DapernoGreta LorenzonSilvia MazzuoliMariabeatrice PrincipiRenato SablichLuisa MoserAntonio FerronatoSara TrainiGherardo TapeteGiorgia BodiniMaria Di GirolamoLaurino GrossiGiammarco MocciChiara RicciSimone SaibeniStefano FestaRocco SpagnuoloClaudio C CortelezziFilippo MocciaroFernando RizzelloAlessandro Armuzzinull nullPublished in: United European gastroenterology journal (2021)
Biological-naïve status and not requiring steroids at Weeks 8 and 14 seem to be associated with a longer persistence on golimumab therapy in ulcerative colitis.